AstraZeneca and Amgen Present Results of Tezepelumab in P-III NAVIGATOR Study for Severe Asthma at ATS2021

 AstraZeneca and Amgen Present Results of Tezepelumab in P-III NAVIGATOR Study for Severe Asthma at ATS2021

Shots:

  • The P-III NAVIGATOR study involves assessing Tezepelumab + SOC vs PBO + SOC in adults (18–80 yrs.) & adolescents (12–17 yrs.) with severe uncontrolled asthma
  • The results demonstrate superiority in 1EP & 2EP in a broad population i.e., 77% reduction in AAER with blood eosinophil counts (≥300 cells/ microlitre) and FeNO levels (≥25 parts/ billion), 85% reduction in exacerbations that require hospitalizations @52 wks. The pre-specified exploratory analyses showed reductions in AAERs @52 wks. in the overall patient population
  • Final results from the PATHFINDER clinical trial programme will be presented further at ATS in coming wks., including the primary analyses from P-III SOURCE & P-II CASCADE II trials

Click here to­ read full press release/ article | Ref: AstraZeneca | Image: AstraZeneca

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post